Skip to content
ATLAS PREP HQ
Growth Hormone

Ipamorelin

Selective growth-hormone secretagogue pentapeptide and GHSR-1a agonist

Selective growth-hormone secretagogue research designed to stimulate GH release through the ghrelin receptor.

Limited Human Evidence

Route

Subcutaneous.

Common format

10 mg vial

Research focus

GH secretion

Evidence level

Limited Human Evidence

Typical cycle

8–12 weeks

Growth Hormone research motifGrowth Hormone

Ipamorelin in 30 seconds

Atlas Fast Read

What it is

Selective growth-hormone secretagogue pentapeptide and GHSR-1a agonist

Why people care

Selective growth-hormone secretagogue research designed to stimulate GH release through the ghrelin receptor.

Human evidence

Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

Biggest misconception

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Bottom line

Ipamorelin has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims.

Overview

What is Ipamorelin?

Ipamorelin is selective growth-hormone secretagogue pentapeptide and GHSR-1a agonist. Selective growth-hormone secretagogue research designed to stimulate GH release through the ghrelin receptor.

Ipamorelin was developed in the 1990s as a more selective growth-hormone secretagogue. Early human pharmacology suggested GH release with less ACTH/cortisol stimulation than older GHRPs.

Mechanism

How it works

Selectively agonizes GHSR-1a to trigger pituitary GH release. Compared with older GHRPs, early pharmacology suggested less stimulation of ACTH and cortisol at GH-releasing doses.

Research areas

GH secretionIGF-1body compositionrecovery

Evidence

What does the evidence actually say?

Limited Human Evidence

Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Early human pharmacology studies show that ipamorelin can stimulate GH release with relative selectivity compared with older secretagogues. Controlled evidence for meaningful improvements in muscle, fat loss, sleep, recovery, or longevity is limited.

Preclinical evidence

Animal and receptor studies demonstrate selective GHSR agonism and GH release with less ACTH/cortisol stimulation than some older GHRPs. Human pharmacology supports the acute endocrine mechanism.

Knowledge gaps

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community reference: 100–300 mcg/day; 200 mcg/day is listed as a common midpoint.

Frequency

Once daily in the community protocol.

Timing

Often bedtime and/or fasted in research practice to align with GH pulses; no approved timing standard.

Route

Subcutaneous.

Cycle length

8–12 weeks

Reconstitution

Community reference: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; after reconstitution refrigerate 2–8 °C and avoid repeated freeze-thaw.

Monitoring

IGF-1, fasting glucose/HbA1c, edema, BP and symptoms of excessive GH exposure; pituitary function matters to expected response.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Potential GH/IGF-axis effects include edema, joint pain, tingling/carpal-tunnel-like symptoms, headache, flushing, increased appetite in some secretagogues, and worsening glucose tolerance. Injection-site reactions can occur.

Contraindications

Avoid in active malignancy and use extreme caution with uncontrolled diabetes, proliferative retinopathy, untreated pituitary disease, pregnancy/breastfeeding or significant edema. Exact contraindications are not established for research formulations.

Interactions

GH/IGF signaling can alter glucose control, so insulin and other glucose-lowering therapy may require closer monitoring. Glucocorticoids can blunt GH effects; thyroid status can influence response. Formal interaction data are limited for research secretagogues.

Stacks

Common stacks

CJC-1295 no-DAC + Ipamorelin

Pairs GHRH-receptor stimulation with ghrelin-receptor stimulation to amplify a GH pulse.

Human endocrine rationale exists; no strong outcome trials for anti-aging/body composition.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Ipamorelin has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims. The most defensible use of the literature is to separate what has actually been measured in people from what is still extrapolated from mechanism or animal work.

More in Growth Hormone

Growth Hormone

CJC-1295 DAC

Long-acting GHRH analog research designed to extend growth-hormone signaling over multiple days.

Read guide

Growth Hormone

CJC-1295 NO DAC + Ipamorelin

GHRH plus growth-hormone secretagogue research intended to support more pulsatile GH release.

Read guide

Growth Hormone

GHRP-2

Ghrelin-receptor agonist research focused on stimulating growth-hormone secretion.

Read guide